Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes.

Détails

ID Serval
serval:BIB_6C66272E758C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes.
Périodique
Clinical physiology and functional imaging
Auteur(s)
July M., Santhanam P., Giovanella L., Treglia G.
ISSN
1475-097X (Electronic)
ISSN-L
1475-0961
Statut éditorial
Publié
Date de publication
01/2018
Peer-reviewed
Oui
Volume
38
Numéro
1
Pages
4-9
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The aim of this review was to summarize the recent developments on the role of positron emission tomography (PET) imaging using different radiopharmaceuticals in patients with multiple endocrine neoplasia (MEN) syndromes. Although most guidelines do not mention the use of PET imaging in patients with MEN syndromes, recent data seem to suggest a relevant diagnostic role of PET imaging in this setting. In particular, latest evidence has shown that somatostatin receptor PET provides a diagnostic accuracy in detecting MEN syndromes-related neuroendocrine tumours (NETs) higher than that of somatostatin receptor scintigraphy, thus influencing patient management in a significant percentage of cases. 18 F-DOPA PET seems to have a potential role in detecting MEN-2-related NETs, whereas 18 F-FDG PET is potentially useful in identifying aggressive NETs with poorer outcomes. More studies are needed to better define the role of different radiotracer-based PET imaging in patients with MEN syndromes.

Mots-clé
PET imaging, multiple endocrine neoplasia syndromes, neuroendocrine tumours
Pubmed
Création de la notice
20/08/2017 17:34
Dernière modification de la notice
03/03/2018 18:05
Données d'usage